Abstracts tagged "Clinical Response"

Abstract Number: 347 • 2017 ACR/ARHP Annual Meeting
Disease Burden at One Academic Rheumatology Routine Care Setting Is Similar in Osteoarthritis (OA) and Rheumatoid Arthritis (RA) at First Visit but Significantly Greater in OA at a 6-Month Follow-up Visit
Jacquelin R. Chua¹, Shakeel M. Jamal¹, Isabel Castrejón¹, Najia Shakoor¹, Anne-Marie Malfait², Joel A. Block² and Theodore Pincus², ¹Division of Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Osteoarthritis commonly is regarded as less severe and less debilitating than RA. However, limited data are available for direct comparison of OA versus RA,…
Abstract Number: 421 • 2017 ACR/ARHP Annual Meeting
Serum Calprotectin Is Not Predictive for Successful Dose Reduction or Discontinuation of TNF Inhibitors in RA Patients with Low Disease Activity
Nathan den Broeder¹, Lieke Tweehuysen¹, Noortje van Herwaarden¹, Thomas Vogl², F.H.J. van den Hoogen¹, Rogier Thurlings³ and Alfons A Den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²University of Muenster, Muenster, Germany, ³Rheumatology, Radboudumc, Nijmegen, Netherlands
Background/Purpose: Dose reduction and discontinuation of TNF inhibitors (TNFi) have been shown feasible in a large proportion of RA patients with low disease activity.1 To…
Abstract Number: 422 • 2017 ACR/ARHP Annual Meeting
No Added Predictive Value of Serum Calprotectin for Treatment Response to Adalimumab or Etanercept in RA Patients
Lieke Tweehuysen¹, Nathan den Broeder¹, Leo .A.B. Joosten², Thomas Vogl³, F.H.J. van den Hoogen⁴, Rogier Thurlings⁵ and Alfons A Den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ³University of Muenster, Muenster, Germany, ⁴Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, ⁵Rheumatology, Radboudumc, Nijmegen, Netherlands
Background/Purpose: To date, no clinically useful baseline biomarkers have been found to predict response to TNF inhibitor (TNFi) treatment .1 Calprotectin was shown to be…
Abstract Number: 432 • 2017 ACR/ARHP Annual Meeting
ACPA and RF As Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort
Janet E. Pope¹, Emmanouil Rampakakis², Mohammad Movahedi³, Angela Cesta³, John S. Sampalis⁴ and Claire Bombardier³, ¹Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ²JSS Medical Research, Montreal, QC, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴McGill University, Montreal, QC, Canada
ACPA and RF as Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data From a Rheumatoid Arthritis CohortBackground/Purpose: Positive serology for anti-citrullinated protein antibody…
Abstract Number: 522 • 2017 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 9 Years
Jürgen Wollenhaupt¹, Joel Silverfield², Eun Bong Lee³, Ketti Terry⁴, Kenneth Kwok⁵, Sander Strengholt⁶, Ryan DeMasi⁷ and Lisy Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Capelle aan den IJssel, Netherlands, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here, we report tofacitinib safety and tolerability up to 114…
Abstract Number: 885 • 2017 ACR/ARHP Annual Meeting
48-Week Complete Remission By Ethnic, Sex and Age Subgroups in Patients with Active Lupus Nephritis Treated with Voclosporin
David Wofsy¹, David A. Isenberg², Frédéric A. Houssiau³, Mary Anne Dooley⁴, Neil Solomons⁵ and Simrat Randhawa⁶, ¹Rheumatology, UCSF, San Francisco, CA, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ³Rheumatology, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ⁴UNC Kidney Centre, Chapel Hill, NC, ⁵Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ⁶Medical Affairs, Aurinia Pharmaceuticals, Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel CNI with a favorable metabolic profile, no observed effect on electrolytes, and a predictable dose response potentially eliminating the…
Abstract Number: 1206 • 2017 ACR/ARHP Annual Meeting
Chondroitin Sulfate Reduces Pain and Improves Function in Knee Osteoarthritis Significantly Better Than Placebo, Independently of the Definition of Responders
J-Y Reginster, Bone Cartilage Unit, University of Liege, Liege, Belgium
Background/Purpose: In addition to the assessment of the two co-primary endpoints – pain and function – regulatory agencies recommend the use of responder rates in…
Abstract Number: 1477 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Outcomes As Independent Measures of Treatment Success with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Post-Hoc Analysis of 2 Placebo-Controlled Phase 3 Trials
Vibeke Strand¹, Rita Ganguly², Nan Li³, Prasheen Agarwal³, Shihong Sheng³, Kaiyin Fei³, Kelly McQuarrie³ and Sharon Popik³, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²GlaxoSmithKline, Collegeville, PA, ³Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Sirukumab, a selective, high-affinity, human anti–IL-6 monoclonal antibody, is in development for rheumatoid arthritis (RA) and other diseases. Effects of sirukumab on RA symptoms…
Abstract Number: 84 • 2017 Pediatric Rheumatology Symposium
Predictors of Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
Takayuki Kishi¹, William Warren-Hicks², Michael Ward³, Nastaran Bayat¹, Lan Wu¹, Gulnara Mamyrova⁴, Ira N. Targoff⁵, Frederick Miller¹, Lisa G. Rider¹ and the Childhood Myositis Heterogeneity Study Group, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institute of Health, Bethesda, MD, ²EcoStat, Inc., Mebane, NC, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁵VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Factors affecting treatment (Rx) responses in juvenile dermatomyositis (JDM) are not well understood. We examined a large JDM registry for predictors of excellent Rx…
Abstract Number: 19L • 2016 ACR/ARHP Annual Meeting
Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway
Guro Løvik Goll^1,2, Inge C Olsen³, Kristin K Jorgensen⁴, Merete Lorentzen⁵, Nils Bolstad⁶, Espen A. Haavardsholm⁷, Knut EA Lundin⁸, Cato Mork⁹, Jorgen Jahnsen⁴, Tore K Kvien³ and the NOR-SWITCH study group, ¹Dept of Rheumatoogy, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumathology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept of Gastroenterology, Akershus University Hospital, Lorenskog, Norway, ⁵Dept of Dermatology, Rikshospitalet, Oslo, Norway, ⁶Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, ⁷Diakonhjemmet Hospital, Oslo, Norway, ⁸Dept of gastroenterology, Rikshospitalet, Oslo, Norway, ⁹Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: TNF-inhibitors (TNFi) have improved treatment of spondyloarthritis (SpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA), Crohn’s disease (CD), ulcerative colitis (UC), and chronic plaque…
Abstract Number: 2481 • 2016 ACR/ARHP Annual Meeting
Infliximab Low Levels at Early Stages Predict the Loss of Drug Levels and the Clinical Response at One Year of Treatment in Patients with Rheumatoid Arthritis
Teresa Jurado¹, Chamaida Plasencia-Rodriguez², Ana Martínez³, Victoria Navarro-Compán⁴, Eva Olariaga-Merida⁵, Diana Peiteado⁶, Alejandro Villalba⁶, Gema Bonilla⁶, Cristina Diego⁷, Alejandro Balsa² and Dora Pascual-Salcedo⁸, ¹Immunology, University Hospital La Paz, Madrid, Spain, ²Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, ³Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, ⁴Rheumatology, University Hospital La Paz, Madrid, Spain, ⁵Immunlogy, University Hospital La Paz, Madrid, Spain, ⁶Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁷Immunology, Hospital La Paz. IdiPaz, Madrid, Spain, ⁸Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain
Background/Purpose: The anti-TNF monoclonal antibody Infliximab (Ifx), has proven effective in treating rheumatoid arthritis (RA), although in 40% of cases may fail, mainly due to…
Abstract Number: 2538 • 2016 ACR/ARHP Annual Meeting
Comparison of Intravenous Versus Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis in a Routine Clinical Care Setting: A Preliminary, Time to Response Analysis
Christopher J. Swearingen, Jessica Poon, Hannah Bernstein and Yusuf Yazici, Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: With the availability of multiple biologic agents, each with different modes of action, use of real world registries provide the manner in which to…
Abstract Number: 2758 • 2016 ACR/ARHP Annual Meeting
Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Which Unmet Criteria Are More Prevalent Among Responders?
J. Antonio Avina-Zubieta¹, Andrew Chow², Philip Baer³, John Kelsall⁴, Proton Rahman⁵, Jacqueline Stewart⁶, Boulos Haraoui⁷, Michel Zummer⁸, Emmanouil Rampakakis⁹, Eliofotisti Psaradellis¹⁰, Francois Nantel¹¹, Karina Maslova¹², Cathy Tkaczyk¹³, Brendan Osborne¹³ and Allen J Lehman¹², ¹Arthritis Research Canada, Richmond, BC, Canada, ²Credit Valley Rheumatology, Mississauga, ON, Canada, ³Independent Rheumatology Practice, Scarborough, ON, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ⁶Penticton Regional Hospital, Penticton, BC, Canada, ⁷University of Montreal, Montreal, QC, Canada, ⁸Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Minimal disease activity (MDA) is now considered an objective target which is more attainable in psoriatic arthritis (PsA) compared to remission (DAS28 <2.6) which…
Abstract Number: 2824 • 2016 ACR/ARHP Annual Meeting
Lack of Partial Renal Response By 12 Weeks after Induction Therapy Is an Indicator to Switch the Treatment in Lupus Nephritis Class III or IV for Reducing Future Damage Accrual
Hironari Hanaoka¹, Hidehiro Yamada², Tomofumi Kiyokawa³, Harunobu Iida¹, Takeshi Suzuki¹, Yoshioki Yamasaki⁴, Seido Ooka⁵, Hiroko Nagafuchi³, Takahiro Okazaki³, Daisuke Ichikawa⁶, Sayuri Shirai⁶, Yugo Shibagaki⁷, Junki Koike⁸ and Shoichi Ozaki³, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan, ³Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Internal Medicie, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁶Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁷Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, K, Japan, ⁸Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Lupus nephritis (LN) class III or IV is associated with a poor prognosis for both patient and renal survival. The guideline or recommendation for…
Abstract Number: 2920 • 2016 ACR/ARHP Annual Meeting
The Effect of Rituximab on B Cells in Skin and Peripheral Blood in Systemic Sclerosis
Maaike Boonstra¹, Annemarie L. Dorjée¹, Koen D. Quint², Tom W.J. Huizinga¹, Hans U. Scherer³ and Jeska K. de Vries-Bouwstra¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Dermatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Open-label studies provided evidence for possible efficacy of rituximab (RTX) in systemic sclerosis (SSc). Previously, we reported on a randomized placebo-controlled clinical trial in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].